The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.
 
Jean Jacques Grob
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Research Funding - Roche
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo
Consulting or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Lilly; Merck; Momenta Pharmaceuticals; Novartis; Oncoceutics; Sanofi; Viralytics
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - GlaxoSmithKline; Sanofi
 
Georgina V. Long
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Provectus; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MERCK; Novartis; Provectus; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech
 
Paul D. Nathan
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Research Funding - AstraZeneca (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Dirk Schadendorf
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; MedImmune; Merck; Novartis; Pierre Fabre
 
Caroline Robert
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
 
Stephen R. Lane
Employment - GlaxoSmithKline; Johnson & Johnson (I); Novartis
Stock and Other Ownership Interests - GlaxoSmithKline; Johnson & Johnson (I); Novartis
Travel, Accommodations, Expenses - Novartis
Other Relationship - Novartis
 
Carmen Mak
Employment - Novartis
 
Philippe Legenne
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Michael A. Davies
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi; Vaccinex
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst)